ScinoPharm Taiwan (神隆) announced on the 5th that it has successfully obtained US FDA approval for its Glatiramer Acetate (GA) Injection, indicated for the treatment of Multiple System Atrophy (MS). This marks ScinoPharm as the first pharmaceutical company in Taiwan to pass this high-difficulty regulatory review, signaling the nation's entry into high-barrier, globally competitive markets.

Key Technical and Market Insights:

• Market Potential: There are approximately 2.9 million MS patients globally, with nearly 1 million in the US. The global market for GA was valued at US$1.5 billion in 2024 and is projected to reach US$2.8 billion by 2033.
• Regulatory Rigor: Since its 1996 debut, GA has been considered one of the most challenging generics to develop. The FDA classifies it under Non-Biological Complex Drugs (NBCDs), requiring stringent verification of process reproducibility, quality consistency, and bioequivalence far beyond standard generics.
• Manufacturing Excellence: ScinoPharm utilized dozens of high-end analytical techniques and statistical methods to ensure stable parameters for the highly diverse synthesis products, eventually validating quality through bioactivity assays identical to the reference drug.

Resource: 神隆獲MS美國製劑藥證 攻7.1億美元市場